vimarsana.com
Home
Live Updates
Telix Submits Biologics License Application (BLA) for TLX250
Telix Submits Biologics License Application (BLA) for TLX250
Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it...
Related Keywords
Canada ,
United Kingdom ,
United States ,
Japan ,
Belgium ,
Australia ,
Melbourne ,
Victoria ,
Switzerland ,
Australian ,
Alvin Carrie Meinhardt ,
Cdx Zircaix ,
Brian Shuch ,
Christian Behrenbruch ,
James Stonecypher ,
Kyahn Williamson ,
Australian Therapeutic Goods Administration ,
Telix Pharmaceuticals Limited ,
Telix Group ,
Corporate Communications ,
Institute Of Urologic Oncology ,
Telix Pharmaceuticals ,
Telix Pharmaceuticals Limited Disclosure Committee ,
Kidney Cancer Research ,
Australian Securities Exchange ,
Drug Administration ,
Health Canada ,
Kidney Cancer Program ,
Biologics License Application ,
Breakthrough Therapy ,
Priority Review ,
Managing Director ,
Chief Development Officer ,
Professor Brian Shuch ,
Carrie Meinhardt Endowed Chair ,
Urologic Oncology ,